Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Nat Med
    February 2026
  1. MURCIANO-GOROFF YR, Stadler ZK
    Preventive vaccines for hereditary cancer syndromes.
    Nat Med. 2026 Feb 26. doi: 10.1038/s41591-026-04248.
    >> Share

  2. WEISOVA P, Scheiblauer S, Ecker J, Schneider M, et al
    Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.
    Nat Med. 2026 Feb 6. doi: 10.1038/s41591-025-04197.
    >> Share

    January 2026
  3. KIM K, Title B, Kipnis J
    Placebo effect influences vaccine responses.
    Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04168.
    >> Share

  4. LUBIANIKER N, Koren T, Djerasi M, Sirotkin M, et al
    Upregulation of reward mesolimbic activity and immune response to vaccination: a randomized controlled trial.
    Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04140.
    >> Share

  5. D'ALISE AM, Willis J, Duzagac F, Hall MJ, et al
    Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.
    Nat Med. 2026 Jan 16. doi: 10.1038/s41591-025-04182.
    >> Share

  6. RASMUSSEN AL
    US vaccine policy must put America first.
    Nat Med. 2026 Jan 9. doi: 10.1038/d41591-026-00002.
    >> Share

  7. KAPULU MC, Orenge F, Kimani D, Kibwana E, et al
    Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.
    Nat Med. 2026 Jan 6. doi: 10.1038/s41591-025-04107.
    >> Share

  8. SIMONS D, Watson-Jones D, Manno D, Friant S, et al
    A One Health trial design to accelerate Lassa fever vaccines.
    Nat Med. 2026 Jan 2. doi: 10.1038/s41591-025-04018.
    >> Share

  9. WONG GL, Yuen MF, Lin B, Douglas MW, et al
    Elebsiran and PEG-IFNalpha for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
    Nat Med. 2026;32:151-159.
    >> Share

    December 2025
  10. POLISKY V, Littmann M, Triastcyn A, Horn M, et al
    Varicella-zoster virus reactivation and the risk of dementia.
    Nat Med. 2025;31:4172-4179.
    >> Share

    November 2025
  11. O'LEARY K
    A much-needed vaccine for Nipah virus.
    Nat Med. 2025 Nov 26. doi: 10.1038/d41591-025-00068.
    >> Share

  12. BARETTI M, Kirk AM, Ladle BH, Kamdar Z, et al
    A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.
    Nat Med. 2025 Nov 24. doi: 10.1038/s41591-025-03995.
    >> Share

  13. RIBEIRO DOS SANTOS G, Jawed F, Mukandavire C, Deol A, et al
    Author Correction: Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.
    Nat Med. 2025 Nov 10. doi: 10.1038/s41591-025-04065.
    >> Share

    October 2025
  14. NAIR NP, Reddy SN, Giri S, Varghese T, et al
    Author Correction: Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.
    Nat Med. 2025 Oct 27. doi: 10.1038/s41591-025-04062.
    >> Share


  15. Rotavirus vaccine reduces gastroenteritis hospitalizations in Indian children.
    Nat Med. 2025 Oct 15. doi: 10.1038/s41591-025-04034.
    >> Share

  16. KAMPMANN B, Hucko A
    Ebola vaccine safe for mothers and infants.
    Nat Med. 2025 Oct 9. doi: 10.1038/s41591-025-04000.
    >> Share

  17. CHEN WH, Barnes RS, Sikorski MJ, Datar R, et al
    A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2025 Oct 8. doi: 10.1038/s41591-025-04003.
    >> Share

  18. NAIR NP, Reddy SN, Giri S, Thiyagarajan V, et al
    Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.
    Nat Med. 2025 Oct 7. doi: 10.1038/s41591-025-03998.
    >> Share

    September 2025
  19. NYOMBAYIRE J, Ingabire R, Mazzei A, Sharkey T, et al
    Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.
    Nat Med. 2025 Sep 8. doi: 10.1038/s41591-025-03932.
    >> Share

  20. CHU HY, Janes H, Carone M, Gilbert PB, et al
    Improving the evidence base for COVID-19 vaccines.
    Nat Med. 2025 Sep 4. doi: 10.1038/s41591-025-03908.
    >> Share

    August 2025
  21. O'LEARY K
    Aluminum in childhood vaccines not linked to chronic diseases.
    Nat Med. 2025 Aug 29. doi: 10.1038/d41591-025-00055.
    >> Share

  22. SHI W, Wohlwend J, Wu M, Barzilay R, et al
    Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model.
    Nat Med. 2025 Aug 28. doi: 10.1038/s41591-025-03917.
    >> Share

  23. WAINBERG ZA, Weekes CD, Furqan M, Kasi PM, et al
    Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
    Nat Med. 2025 Aug 11. doi: 10.1038/s41591-025-03876.
    >> Share

  24. KEELEY AJ, Camara FE, Armitage EP, de Crombrugghe G, et al
    Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.
    Nat Med. 2025 Aug 8. doi: 10.1038/s41591-025-03868.
    >> Share

    July 2025
  25. ZITVOGEL L
    Rethinking chemotherapy as an indirect vaccine.
    Nat Med. 2025 Jul 24. doi: 10.1038/s41591-025-03804.
    >> Share

    June 2025

  26. Chikungunya virus burden and implications for vaccination programs.
    Nat Med. 2025 Jun 27. doi: 10.1038/s41591-025-03812.
    >> Share

  27. CRACKNELL DANIELS B, Ferguson NM, Dorigatti I
    Efficacy, public health impact and optimal use of the Takeda dengue vaccine.
    Nat Med. 2025 Jun 25. doi: 10.1038/s41591-025-03771.
    >> Share

  28. RIBEIRO DOS SANTOS G, Jawed F, Mukandavire C, Deol A, et al
    Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.
    Nat Med. 2025 Jun 10. doi: 10.1038/s41591-025-03703.
    >> Share

  29. NDEMBI N, Mutesa L, Muvunyi CM, Kim JH, et al
    Bridging the vaccine divide.
    Nat Med. 2025 Jun 2. doi: 10.1038/s41591-025-03728.
    >> Share

    May 2025
  30. SHORE ND, Powles TB, Bedke J, Galsky MD, et al
    Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
    Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03738.
    >> Share

  31. O'LEARY K
    Measles to become endemic in the USA if vaccination rates continue to fall.
    Nat Med. 2025 May 14. doi: 10.1038/d41591-025-00031.
    >> Share

  32. PEREZ-ESTIGARRIBIA PE, Ribeiro Dos Santos G, Cauchemez S, Vazquez C, et al
    Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks.
    Nat Med. 2025 May 1. doi: 10.1038/s41591-025-03684.
    >> Share

  33. GARRETSON TA, Liu J, Li SH, Scher G, et al
    Immune history shapes human antibody responses to H5N1 influenza viruses.
    Nat Med. 2025;31:1454-1458.
    >> Share

    April 2025
  34. O'LEARY K
    Antibiotics reduce vaccine responses in infants.
    Nat Med. 2025 Apr 30. doi: 10.1038/d41591-025-00028.
    >> Share


  35. Combating vaccine revisionism.
    Nat Med. 2025 Apr 7. doi: 10.1038/s41591-025-03682.
    >> Share

  36. HOU Z, Wu Z, Qu Z, Gong L, et al
    A vaccine chatbot intervention for parents to improve HPV vaccination uptake among middle school girls: a cluster randomized trial.
    Nat Med. 2025 Apr 7. doi: 10.1038/s41591-025-03618.
    >> Share

    March 2025
  37. RUDMAN SPERGEL AK, Ananworanich J, Guo R, Deng W, et al
    mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial.
    Nat Med. 2025 Mar 18. doi: 10.1038/s41591-025-03591.
    >> Share

  38. ADAMU AA, Ndwandwe D, Wiysonge CS
    Leveraging implementation science in clinical trials of vaccines in the global south.
    Nat Med. 2025 Mar 5. doi: 10.1038/s41591-025-03546.
    >> Share

    January 2025
  39. DU Z, Pandey A, Moghadas SM, Bai Y, et al
    Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults.
    Nat Med. 2025 Jan 9. doi: 10.1038/s41591-024-03431.
    >> Share

  40. GOSWAMI D, Kappe SHI
    Setting sights on a single-shot malaria vaccine.
    Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03427.
    >> Share

    October 2024
  41. WAIRAGKAR N, Ismail AJ, Abouhussein DMN, Adeyeye MC, et al
    Regulatory reforms will boost African vaccine production and access.
    Nat Med. 2024 Oct 29. doi: 10.1038/s41591-024-03314.
    >> Share


  42. Lassa vaccines to save lives, spare economies and assist in pandemic preparedness.
    Nat Med. 2024 Oct 11. doi: 10.1038/s41591-024-03332.
    >> Share

    September 2024
  43. NGUYEN DC, Hentenaar IT, Morrison-Porter A, Solano D, et al
    SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination.
    Nat Med. 2024 Sep 27. doi: 10.1038/s41591-024-03278.
    >> Share

  44. WEBBY RJ
    The practical longevity of stockpiled A(H5N1) influenza vaccine.
    Nat Med. 2024 Sep 26. doi: 10.1038/s41591-024-03256.
    >> Share

    August 2024
  45. JOHANSEN ND, Vaduganathan M, Bhatt AS, Modin D, et al
    Electronic nudges for sustained influenza vaccination uptake in older adults: the nationwide randomized NUDGE-FLU-2 trial.
    Nat Med. 2024 Aug 30. doi: 10.1038/s41591-024-03202.
    >> Share

  46. SMITH DRM, Turner J, Fahr P, Attfield LA, et al
    Health and economic impacts of Lassa vaccination campaigns in West Africa.
    Nat Med. 2024 Aug 28. doi: 10.1038/s41591-024-03232.
    >> Share

  47. DEREJE N, Fallah MP, Ndembi N, Duga A, et al
    A community engagement framework to accelerate the uptake of malaria vaccines in Africa.
    Nat Med. 2024 Aug 22. doi: 10.1038/s41591-024-03193.
    >> Share

    July 2024
  48. SUN K, Bhiman JN, Tempia S, Kleynhans J, et al
    SARS-CoV-2 correlates of protection from infection against variants of concern.
    Nat Med. 2024 Jul 26. doi: 10.1038/s41591-024-03131.
    >> Share

  49. TAQUET M, Dercon Q, Todd JA, Harrison PJ, et al
    The recombinant shingles vaccine is associated with lower risk of dementia.
    Nat Med. 2024 Jul 25. doi: 10.1038/s41591-024-03201.
    >> Share

  50. KHURANA S, King LR, Manischewitz J, Posadas O, et al
    Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.
    Nat Med. 2024 Jul 16. doi: 10.1038/s41591-024-03189.
    >> Share

  51. MAY M
    How mRNA is powering a personalized vaccine revolution.
    Nat Med. 2024 Jul 15. doi: 10.1038/d41591-024-00052.
    >> Share

  52. XU H, Zou K, Dent J, Wiens KE, et al
    Author Correction: Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Jul 9. doi: 10.1038/s41591-024-03176.
    >> Share

    June 2024
  53. ZHONG Y, Kang AYH, Tay CJX, Li HE, et al
    Publisher Correction: Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
    Nat Med. 2024 Jun 10. doi: 10.1038/s41591-024-03107.
    >> Share

  54. LI R, Shah PH, Stewart TF, Nam JK, et al
    Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
    Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03025.
    >> Share

  55. LAZARUS JV, White TM, Wyka K, Ratzan SC, et al
    Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023.
    Nat Med. 2024;30:1559-1563.
    >> Share

  56. CLIFF M, Welaga P, Mohammed N, Ansah P, et al
    Strategies for controlling pneumococcal disease and outbreaks during humanitarian emergencies.
    Nat Med. 2024;30:1515-1516.
    >> Share

    May 2024
  57. MENTZER AJ, Dilthey AT, Pollard M, Gurdasani D, et al
    High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02944.
    >> Share

    April 2024
  58. ZHONG Y, Kang AYH, Tay CJX, Li HE, et al
    Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02962.
    >> Share

  59. SARAF A, Gurjar R, Kaviraj S, Kulkarni A, et al
    An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
    Nat Med. 2024 Apr 18. doi: 10.1038/s41591-024-02955.
    >> Share

  60. ARNOLD C
    'Inverse vaccines' could treat autoimmune disease - from multiple sclerosis to celiac disease.
    Nat Med. 2024 Apr 10. doi: 10.1038/d41591-024-00024.
    >> Share

  61. YARCHOAN M, Gane EJ, Marron TU, Perales-Linares R, et al
    Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
    Nat Med. 2024 Apr 7. doi: 10.1038/s41591-024-02894.
    >> Share


  62. Systematic testing in cholera surveillance enhances vaccine impact and cost-effectiveness.
    Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
    >> Share

    March 2024
  63. O'LEARY K
    Going the extra mile to increase vaccine uptake.
    Nat Med. 2024 Mar 28. doi: 10.1038/d41591-024-00022.
    >> Share

  64. RAPPAPORT AR, Kyi C, Lane M, Hart MG, et al
    A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2024 Mar 27. doi: 10.1038/s41591-024-02851.
    >> Share

  65. XU H, Zou K, Dent J, Wiens KE, et al
    Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Mar 5. doi: 10.1038/s41591-024-02852.
    >> Share

    February 2024
  66. PERETTI-WATEL P, Verger P, Ward JK
    To understand mRNA vaccine hesitancy, stop calling the public anti-science.
    Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016